Haifeng Pan, Siyuan Yu, Haoyun Zhuang, Han Yang, Jinlu Jiang, Haihui Yang, Shuling Ren, Guoxing Luo, Xuan Yu, Shuping Chen, Yanhua Lin, Roufang Sheng, Shiyin Zhang, Quan Yuan, Chenghao Huang, Tianying Zhang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia
The intrinsic pharmacokinetic limitations of traditional peptide-based cancer vaccines hamper effective cross-presentation and codelivery of antigens and adjuvants, which are crucial for inducing robust antitumor CD8+ T-cell responses. Here, we report the development of a versatile strategy that simultaneously addresses the different pharmacokinetic challenges of soluble subunit vaccines composed of antigens and CpG to modulate vaccine efficacy via translating an engineered chimeric peptide, eTAT, as an intramolecular adjuvant...
April 17, 2024: Cancer Immunology Research